Physician profile
Tanner A Beard
NPI 1649902420
$1,826.19
in general payments reported to CMS, 2019-2025
12 companies · $637 in 2025
The $637 reported for 2025 was more than what 83% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $74.26 · 2023: $321 · 2024: $793 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,751.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $434.35 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $243.50 | 2022-2025 | Tyrvaya, Ryzumvi |
| Abbvie INC. | $202.79 | 2023-2025 | Lumigan, Alphagan P, Vuity |
| Alcon Vision LLC | $200.24 | 2023-2025 | Rocklatan, Total30 |
| Bausch & Lomb Americas INC. | $189.58 | 2023-2025 | Miebo, Infuse, Vyzulta |
| Biotissue Holdings INC. | $164.25 | 2023-2024 | |
| Topcon Healthcare, INC. | $160.56 | 2025 | |
| Mallinckrodt Hospital Products INC. | $119.34 | 2024-2025 | Acthar |
| Astellas Pharma US INC | $31.09 | 2024 | Izervay |
| Dompe US, INC. | $29.01 | 2025 | Oxervate |
| Johnson & Johnson Vision Care, INC. | $28.46 | 2023 | Acuvue |
| Rxsight INC | $23.02 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens, Rxsight Injector Cartridge |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanner Beard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.